Finally, PD-L1/PD1 upregulation enhanced by the obese-related low chronic inflammatory state could be exploited to improve the immune checkpoint inhibitors treatment activity, especially in patients diagnosed with TNBC, which is known to be the most immunogenic breast cancer subtype. The gene discussed is PDCD1; the disease is breast cancer.